Skip to main content
Anixa Biosciences Inc logo

Anixa Biosciences Inc — Investor Relations & Filings

Ticker · ANIX ISIN · US45069V2034 LEI · 549300PW2C2QTAJL2D19 US Professional, scientific and technical activities
Open in API
Filings indexed 958 across all filing types
Latest filing 2017-07-20 Board/Management Inform…
Country US United States of America
Listing US ANIX

About Anixa Biosciences Inc

https://www.anixa.com/

Anixa Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapies and vaccines for the treatment and prevention of cancer. The company's portfolio is centered on two main platforms: a therapeutics program and a vaccine program. The therapeutics portfolio features a Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy, which genetically engineers a patient's own immune cells to target and destroy solid tumors. The vaccine portfolio includes preventative and therapeutic candidates for various cancers, with a primary focus on breast and ovarian cancer, and discovery programs for lung, colon, and prostate cancer. Anixa aims to address critical unmet needs in oncology through these innovative approaches.

Recent filings

Filing Released Lang Actions
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated July 17, 2017, reporting the appointment of a new director to the company's Board of Directors. The key section is Item 5.02, which specifically addresses the departure or appointment of directors or certain officers. The content focuses on the appointment of Mr. Lewis Titterton to the Board and related compensatory arrangements. There is no financial data or earnings information, nor is this a full annual or quarterly report. The document is clearly an announcement of a board/management change, fitting the category of Board/Management Information (MANG). The document length is about 4874 characters, which is consistent with a detailed announcement rather than a brief notice or a full report. Therefore, the correct classification is MANG with high confidence.
2017-07-20 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated July 6, 2017, reporting the appointment of new senior executives (President, CEO, and COO) and the resignation of the previous CEO and director. The content focuses on changes in the company's board and senior management personnel, including biographical details and compensation arrangements. There are no financial statements or earnings data presented. The primary subject is the announcement of management changes, which aligns with the category for Board/Management Information (MANG). The document length (7997 characters) supports it being a full report rather than a brief announcement. Therefore, the appropriate classification is MANG with high confidence.
2017-07-12 English
SCHEDULE 13D/A
Major Shareholding Notification
2017-06-22 English
SCHEDULE 13D/A
Major Shareholding Notification
2017-06-21 English
PRIMARY DOCUMENT
Director's Dealing
2017-06-06 English
PRIMARY DOCUMENT
Director's Dealing
2017-06-05 English

Browse filings by year

32 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.